GOP senators have introduced legislation they say would protect provisions for preexisting conditions under the Affordable Care Act; Cigna shareholders have voted in favor of the acquisition of pharmacy benefit manager Express Scripts; and study results show that aspirin does not lower cardiovascular (CV) risk in the long-term.
GOP Senators Introduce Bill to Protect Preexisting Conditions
GOP senators have introduced legislation that they say would preserve provisions for people with preexisting conditions under the Affordable Care Act, reported The Hill. The senators said their bill would amend federal law to guarantee access to health insurance for all Americans, including those with preexisting conditions. The legislation would also prevent insurers from increasing premiums for individuals with preexisting conditions. However, critics say the bill would allow insurers to exclude coverage of preexisting conditions.
Shareholders Approve Cigna—Express Scripts Deal
Cigna shareholders have approved the proposed $52 billion acquisition of pharmacy benefit manager Express Scripts. According to Reuters, 90% of shareholders voted in favor of the merger, which is expected to close by the end of 2018. The approval follows Carl Icahn’s attempt to sway shareholders against the deal.
Aspirin Does Not Lower CV Risk in Long-Term
According to study results coming out of the Aspirin to Reduce Risk of Initial Vascular Events trial, a daily dose of 100 mg of aspirin was not associated with a reduction in long-term risk for cardiovascular (CV) or cerebrovascular events. The trial randomly assigned over 12,000 nondiabetic adults with multiple CV risk factors but no history of CV events, reported Medscape.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
2 Commerce Drive
Cranbury, NJ 08512